3rd Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference

New York, New York
Thursday, October 04, 2012
NEW - A copy of the program brochure with the schedule and detailed information can be accessed by clicking here

Schedule & Sponsors:

7:30am
- Registration/coffee and pastries
8:00am - Program begins
10:30am - Coffee break (Progenitor Cell Therapy)
12:15pm
- Lunch (sponsored by JMP Securities)
2:15pm
- Dessert break (sponsored by ROTH Capital)
5:15pm - Program concludes with wine and cheese networking reception (sponsored by Cantor Fitzgerald)

Morning Keynote "Cancer Immunotherapy: The End of the Beginning" by:

Jedd D. Wolchok, M.D., Ph.D.

Dr. Wolchok is Associate Attending Physician at Memorial Sloan-Kettering Cancer Center (MSKCC) and Associate Director of the Ludwig Center for Cancer Immunotherapy, as well as Director of Immunotherapy Clinical Trials. His expertise is in the treatment of metastatic melanoma. His specific area of research interest is the pre-clinical and clinical development of novel immunologic therapies. Dr. Wolchok was instrumental in the clinical development leading to the approval of ipilimumab for advanced melanoma.

Luncheon Keynote Speaker "My Career and Cancer Immunotherapy":

Robert Bazell

Robert Bazell is NBC News' Chief Science and Health Correspondent. His reports appear on "NBC Nightly News, with Brian Williams" "Today" and "Dateline NBC." During his career with NBC News, which has spanned more than three decades, Bazell has reported on a wide range of subjects in the areas of science, technology and medicine throughout the United State and around the world. Bazell has received hundreds of awards for his reports, including four Emmys, the Alfred I. DuPont Columbia Award, the Edward R. Murrow Award and a Gracie Award. He has also received a George Foster Peabody Award, for which he was recognized for exemplifying "the best reporting on science and medicine. From transmission of the AIDS virus to innovations in cancer treatment from the perceived dangers of cellular phones to alternative modes of health care, Mr. Bazell brings intelligence, understanding and reportorial excellence to the task. Robert Bazell is an outstanding television reporter who recognizes when to speak, when to listen and when to tell."

Confirmed participants for 2012:

Presenting companies:
  • Agenus Inc. (AGEN)
  • Argos Therapeutics (private)
  • Bavarian Nordic (BAVA.CO)
  • BioSante Pharmaceuticals (BPAX)
  • DCPrime (private)
  • Dendreon Corporation (DNDN)
  • Galena Biopharma (GALE)
  • HEAT Biologics (private)
  • Idera Pharmaceuticals, Inc. (IDRA)
  • Immune Design Corp (private)
  • ImmunoCellular Therapeutics (IMUC)
  • NewLink Genetics (NLNK)
  • Northwest Biotherapeutics (NWBO)
  • OncoSec Medical Incorporated (ONCS)
  • Prima Biomed (PBMD)
  • Provectus Pharmaceuticals (PVCT)
  • Serametrix (private)
  • Vical Incorporated (VICL)
Speakers:
  • Garo Armen, Ph.D., Agenus
  • Marnix L. Bosch, Ph.D., Northwest Biotherapeutics
  • Courtney Crane, Ph.D., University of Washington
  • Mark Frohlich, M.D., Dendreon
  • Frank T. Gentile, Ph.D., Hambrecht & Quist Capital Management
  • Mara Goldstein, Cantor Fitzgerald
  • Carl Gordon, Ph.D., C.F.A., OrbiMed
  • James Gulley, M.D., Ph.D., F.A.C.P., National Cancer Institute
  • Peter Ho, Ph.D., ImmunoCellular Therapeutics
  • Reiner Laus, M.D., Bavarian Nordic
  • Charles J. Link, Jr., M.D., NewLink Genetics
  • Rosemary Mazanet, M.D., Ph.D., Galena Biopharma
  • Frederick Miesowicz, Ph.D., Argos Therapeutics
  • Joseph Pantginis, Ph.D., ROTH Capital Partners
  • Stelios Papadopoulos, Ph.D.
  • Michail Papamichail, M.D., Ph.D., Saint Savas Cancer Hospital
  • Andrew T. Parsa, M.D., Ph.D., University of California, San Francisco
  • Marc Pentopoulos, C.F.A., Symmetry Capital
  • Col. George E. Peoples, M.D., F.A.C.S., Brooke Army Medical Center
  • Sonia Perez, Ph.D., Saint Savas Cancer Hospital
  • Daniel P. Petrylak, M.D., Yale Cancer Center
  • David Sable, M.D., Special Situations Life Sciences Fund
  • Joel Sendek, Stifel Financial
  • Susan Slovin, M.D., Ph.D., F.A.C.P., Memorial Sloan-Kettering Cancer Center
  • Y. Katherine Xu, Ph.D., William Blair
Please find below some information from last year's (2011) event:

Download a copy of the program brochure (PDF): click here

Video replay of sessions from the event - click here

Photo gallery from 2011 event - click here

The following companies presented at the 2011 conference
  • Aduro BioTech, Inc. (private)
  • Agenus Inc. (AGEN)
  • AgonOx (private)
  • Antigen Express Inc. (GNBT)
  • Argos Therapeutics (private)
  • AVAX Technologies, Inc. (AVXT)
  • Bavarian Nordic (BAVA.CO)
  • BioSante Pharmaceuticals (BPAX)
  • Biovest International, Inc. (BVTI)
  • Celldex Therapeutics (CLDX)
  • DCPrime (private)
  • GENEIUS, Inc. (private)
  • Idera Pharmaceuticals, Inc. (IDRA)
  • ImmunoCellular Therapeutics Ltd (IMUC)
  • Inovio Pharmaceuticals (INO)
  • Jennerex, Inc. (private)
  • Northwest Biotherapeutics (NWBO)
  • OncoSec Medical Incorporated (ONCS)
  • Provectus (PVCT)
  • RXi Pharmaceuticals/Galena (RXII)
  • Serametrix (private)
Speakers at the 2011 conference included (alphabetical order):
  • Garo Armen, Agenus Inc.
  • Sudhir Agrawal, D. Phil., F.R.S.C., Idera Pharmaceuticals
  • Reni J. Benjamin, Ph.D., Rodman & Renshaw, LLC
  • David Berd, M.D., Cancer Treatment Centers of America
  • Faith Charles, Partner, Thompson Hine LLP
  • Charles C. Duncan, Ph.D., JMP Securities LLC
  • Frank T. Gentile, Ph.D., Hambrecht & Quist Capital Management
  • Mara Goldstein, Cantor Fitzgerald
  • Carl Gordon, Ph.D., C.F.A., OrbiMed
  • James Gulley, M.D., Ph.D., F.A.C.P., National Cancer Institute
  • Tibor Keler, Ph.D., Celldex Therapeutics
  • Karen Langfeld, GlaxoSmithKline
  • Reiner Laus, M.D., Bavarian Nordic
  • Frederick M. Miesowicz, Ph.D., Argos Therapeutics
  • Joseph Pantginis, Ph.D., ROTH Capital Partners
  • Andrew T. Parsa, M.D., Ph.D., University of California, San Francisco
  • Col. George E. Peoples, M.D., F.A.C.S., Brooke Army Medical Center
  • Bernard Peperstraete, M.D., NGN Capital
  • David Sable, M.D., Special Situations Life Sciences Fund
  • Rajeev Shah, RA Capital Management, LLC
  • Susan Slovin, M.D., Ph.D., F.A.C.P., Memorial Sloan-Kettering Cancer Center
  • Timothy R. Wright, Signal Hill Advisors & Agenus Inc.
  • Y. Katherine Xu, Ph.D., William Blair & Company LLC

Attendees from past events included:

203 Investment Partners
Advaxis
Aegis Capital Corp.
AGS Capital
Alliance for Cancer Gene Therapy Foundation [ACGT]
Arcus Ventures
Argos Therapeutics
Aspire Capital
Atlantic Capital
BAM Capital
Bavarian Nordic A/S
Baxter Healthcare Corporation
Belsize Asset Management GmbH
BioBusiness.TV
BioMedTracker
BioOne Capital
BioSante Pharmaceuticals, Inc.
Biovest International, Inc.
BioYields
Black Diamond
BN ImmunoTherapeutics, Inc.
Boenning & Scattergood, Inc.
Brean Murray Carret & Co
Brightline
Burnham Asset Management
Canaccord Genuity
Cancer Research Institute
Cancer Treatment Centers of America
Caris & Co.
Celgene Corporation
Celldex Therapeutics, Inc.
Center for Performance Investing
Cerulean BioVentures
Coleman Research Group
Continuum Partners
Dartmouth Medical School
Dawson James Securities Inc.
Deerfield Management
Delta Capital Management
Delwar Capital
Dendreon Corporation
Deutsche Bank
DierePharma
DLS Research, LLC
Duquesne
Ennis Biotechnology Capital
Farahi Investment Co.
Favus Institutional Research LLC
Ferghana Partners / BioBusiness.TV
FIC Capital
First Analysis
FMB Research
Forbes
Fred Hutchinson Cancer Research Center
Griffin Securities, Inc.
HealthPro BioVentures LLC
Hospital European Georges Pompidou
ImmunoCellular Therapeutics Ltd.
Ingalls & Snyder
Inovio Pharmaceuticals, Inc.
institut pasteur
Institute for International Research
JFS Investments
JMP Securities LLC
Johns Hopkins Sidney Kimmel Cancer Center
JSR Associates
Katz Associates
Kite Pharma, Inc
Ladenburg Thalmann & Co.
LAP LLC
Lazard Capital Markets
Ledgemont Capital Group
Lieberman and Company
Little Gem Life Sciences
MannKind Corporation
Mayfair Capital Partners Inc
MD Becker Partners
Memorial Sloan-Kettering Cancer Center
Meridian Medical
Merrill Datasite
MRM Associates
National Cancer Institute
National Securities Corporation
Needham & Company
New York Biotechnology Association
New York City Investment Fund
New York University (NYU)
Northwest Biotherapeutics, Inc.
NYU Langone Medical School
Ono Pharma USA, Inc.
Opal Capital Management LLC
Opus Point Partners
OrbiMed
Paramount BioCapital
Perseus LLC
Pharmawire
Pinnacle Capital Management
Pioma inc
Porter, LeVay & Rose
PrimaBiomed Ltd.
ProActive Capital Resources Group
Prostate Cancer Foundation
Provectus Pharmaceuticals, Inc.
PSource Capital Ltd
Quantum Immunologics
RA Capital Management LLC
Reedland Capital Partners
Regeneron Pharmaceuticals, Inc.
Reuters
Riverbank Capital
Rodman & Renshaw
Roth Capital
RUSNANO
Sagres Partners
Saunders Murdock Associates
SBS Securities
Seed-One Ventures, LLC
Shanghai Yiting Investment and Management Company
SLJ Associates
Socius Capital
Stanphyl Capital Management
Sterling Atlantic LLC
Symmetry Capital
Technological and Investment Horizons
The Pink Sheet
Thomas, McNerney & Partners
Topeka Management, Inc.
Toucan Capital
TPNA
TVAX Biomedical LLC
University of Pennsylvania
University of Pittsburgh Cancer Institute
Vaccinogen, Inc.
Vatera Healthcare Partners
VeoMed LLC
Waterville Investment Research Inc
WBB Securities, LLC
Wedbush PacGrow Life Sciences
West End Management
Whitebox Advisors
Williver Investments
Yale University
Zeomedex, LLC


 

Contact Information

RegOnlineĀ® by Lanyon is the quick, easy and affordable online event registration and event management software for small and medium-sized events. The solution includes event websites, event marketing tools, mobile event apps, online registration forms, badge maker and more.